Abbott’s AVEIR Dual Chamber Leadless Pacemaker System Gains CE Mark to Treat Abnormal or Slow Heart Rhythms
Shots:
- Abbott’s AVEIR DR leadless pacemaker system has obtained CE Mark for treating patients with abnormal or slow heart rhythms across the EU. It was FDA-approved in Jun 2023
- The system was assessed under the AVEIR DR i2i global trial that reached its 1EPs of safety & efficacy, depicting a system implant success rate of 98.3% with atrioventricular synchrony among >97% of patients, despite of distinct postures & gaits, after 3mos. of implantation
- The AVEIR DR system consists of AVEIR VR (paces right ventricle) & AVEIR AR (paces right atrium). It uses i2i (implant-to-implant) communication technology to synchronize pacing b/w the two devices using high-frequency pulses transmitted through the body's blood
Ref: Abbott | Image: Abbott
Related News:- Abbott’s AVEIR Dual Chamber Leadless Pacemaker System Receives the US FDA’s Approval for Abnormal or Slow Heart Rhythms
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
